First-ever fentanyl overdose prevention vaccine could save thousands of lives annually, with human trials beginning early ...
The drug is not considered a cure, but results from clinical trials point to major advancement for a devastating cancer ...
With a pair of Phase III trial flops, Ultragenyx will explore cost reductions as analysts turn attention to an upcoming ...
Two replicate phase 3 trials of GB-0895, an anti-thymic stromal lymphopoietin antibody, are enrolling adults and adolescents ...
Ultragenyx Pharmaceutical has reported the failure of a pair of late-phase brittle bone disease trials, prompting the biotech to prepare to significantly reduce its spending.
Biohaven didn't receive the clinical readout it was hoping for over the festive period. | As the biopharma wound down for the ...
Ongoing clinical trials are exploring therapies like tolebrutinib, fingolimod, and ocrelizumab, focusing on efficacy and ...
When a biotech company announces positive Phase 3 trial results or receives FDA approval, the market reaction is often immediate and substantial. This is not just speculation. These milestones ...
The US saw several new and expanded FDA indications this year. The top 5 most-read FDA approvals on AJMC.com included 4 novel ...
A redesigned immune-activating cancer drug has produced striking early results in a small clinical trial, shrinking tumors ...
Ambros Therapeutics launches with $125M to advance neridronate, a non-opioid therapy for CRPS-1. See how this Phase 3-ready ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback